Upstream Bio Stock News

– Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites – – Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric receptor complexes – – Data support the potential of verekitug's unique mechanism of action to achieve a differentiated therapeutic effect across a broad range of TSLP-driven severe respirato...

WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on ...

Upstream Bio, Inc. - Special Call Company Participants Meggan Buckwell E. Sutherland - CEO & Director Aaron Deykin - Chief Medical Officer and Head of Research & Development Conference Call Participants Tessa Romero - JPMorgan Chase & Co, Research Division Yaron Werber - TD Cowen, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Matthew Phipps - William Blair & Company ...

– In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in placebo-adjusted endoscopic nasal polyp score (NPS) of -1.8 (p

WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will report top-line data from the Phase 2 VIBRANT trial of verekitug, the only known clinical-stage monoclonal antibody targeting the receptor for thymic stromal l...

Upstream Bio (UPB) Q2 R&D Soars 169%

– On track to report top-line data from Phase 2 trial in chronic rhinosinusitis with nasal polyps (CRSwNP) in the third quarter of 2025 – – Completed enrollment in Phase 2 trial in severe asthma in June 2025; top-line data expected in the first quarter of 2026 – – First patient dosed in Phase 2 trial in chronic obstructive pulmonary disease (COPD) in July 2025 – WALTHAM, Mass., Aug. 06, 2025 (G...

– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD –